GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Cyclically Adjusted PB Ratio

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.29 (As of Apr. 29, 2024)


View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Enzon Pharmaceuticals's current share price is $0.08345. Enzon Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.29. Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.29.

The historical rank and industry rank for Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

ENZN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.26   Max: 0.96
Current: 0.29

During the past years, Enzon Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.96. The lowest was 0.08. And the median was 0.26.

ENZN's Cyclically Adjusted PB Ratio is ranked better than
79.88% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs ENZN: 0.29

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enzon Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $0.047. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.29 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Enzon Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Enzon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.20 0.46 0.69 0.33

Enzon Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.85 0.67 0.51 0.33

Competitive Comparison of Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Enzon Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.08345/0.29
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzon Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Enzon Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.047/129.4194*129.4194
=0.047

Current CPI (Dec. 2023) = 129.4194.

Enzon Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.312 99.695 0.405
201406 0.468 100.560 0.602
201409 0.639 100.428 0.823
201412 0.670 99.070 0.875
201503 0.832 99.621 1.081
201506 0.418 100.684 0.537
201509 0.377 100.392 0.486
201512 0.409 99.792 0.530
201603 0.443 100.470 0.571
201606 0.471 101.688 0.599
201609 0.488 101.861 0.620
201612 0.234 101.863 0.297
201703 0.248 102.862 0.312
201706 0.343 103.349 0.430
201709 0.196 104.136 0.244
201712 0.207 104.011 0.258
201803 0.200 105.290 0.246
201806 0.195 106.317 0.237
201809 0.183 106.507 0.222
201812 0.339 105.998 0.414
201903 0.271 107.251 0.327
201906 0.270 108.070 0.323
201909 0.143 108.329 0.171
201912 0.137 108.420 0.164
202003 0.131 108.902 0.156
202006 0.126 108.767 0.150
202009 0.117 109.815 0.138
202012 -0.446 109.897 -0.525
202103 0.093 111.754 0.108
202106 0.085 114.631 0.096
202109 0.076 115.734 0.085
202112 0.066 117.630 0.073
202203 0.055 121.301 0.059
202206 0.044 125.017 0.046
202209 0.037 125.227 0.038
202212 0.046 125.222 0.048
202303 0.041 127.348 0.042
202306 0.037 128.729 0.037
202309 0.034 129.860 0.034
202312 0.047 129.419 0.047

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enzon Pharmaceuticals  (OTCPK:ENZN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Enzon Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.
Executives
Randolph C Read director C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone director C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick director C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper other: See explanation of responses 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc other: See explanation of responses 2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper other: See explanation of responses 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc. other: See Footnote 1 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp. other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman 10 percent owner, other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn 10 percent owner C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein officer: VP-Finance and PFO
Jonathan Christodoro director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Headlines

From GuruFocus

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2009

Enzon Pharmaceuticals Announces Results of Rights Offering

By Marketwired Marketwired 10-22-2020

Enzon Inc. Reports Operating Results (10-K)

By gurufocus 10qk 03-16-2011

Top Micro-Cap Picks From the Gurus

By Sheila Dang Sheila Dang 06-23-2015

Icahn Files 13D on Enzon Pharma

By gurufocus Todd Sullivan 03-14-2008

Enzon Pharmaceuticals Announces Key Dates for Rights Offering

By Marketwired Marketwired 09-16-2020

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2010

Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals

By Sydnee Gatewood Sydnee Gatewood 12-02-2016